|| Clovis Oncology Inc.
|| Ovarian Cancer
|| Deleterious BRCA mutation associated with advanced ovarian cancer
| Mode of Action
|| PARP inhibitor
| Approval Status
|| FDA approved (USA)
|| 300 mg, 200 mg
Who is rucaparib for?
Rubraca (rucaparib) is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies .
Patients should be selected for therapy based on the FDA-approved FoundationFocus CDxBRCA test (Foundation Medicine Inc.) .
Complete information about Rubraca (rucaparib) dosage and administration can be found here .The standard dosage is:
Patients should be monitored for hematologic toxicity at baseline and monthly thereafter, and use of Rubraca (rucaparib) should be discontinued if myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML) is confirmed .Consult your treating doctor for personalised dosing.
- 600 mg orally twice daily.
What is rucaparib and how does it work?
Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies .
Approximately 15 to 20 % of patients with ovarian cancer have a BRCA gene mutation. BRCA genes are involved with repairing damaged DNA and normally work to prevent tumour development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Rubraca (rucaparib) is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slowdown or stoppage of tumour growth .
What is rucaparib's approval status?
Rubraca (rucaparib) was approved by:
for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies .The approval was based on a study involving 106 adults with BRCA-mutated advanced ovarian cancer who had been treated with two or more chemotherapy regimens. BRCA gene mutations were confirmed in 96 % of tested trial participants with available tumour tissue using the FDA approved diagnostic FoundationFocus CDxBRCA . Of the participants who received Rubraca (rucaparib) in the trials, 54 % experienced complete or partial shrinkage of their tumours lasting a median of 9.2 months .The safety of Rubraca (rucaparib) was evaluated in 377 patients with advanced ovarian cancer. The most common adverse reactions (greater than or equal to 20 %) experienced by patients were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia, constipation, decreased appetite, diarrhea, thrombocytopenia, and dyspnea. MSD/AML was reported in 2 out of 377 (0.5 %) patients with ovarian cancer. In addition, AML was reported in 2 (<1 %) patients with ovarian cancer enrolled in a blinded, randomised trial evaluating rucaparib versus placebo .
- FDA (USA) on December 19, 2016
The most common adverse reactions were nausea, fatigue, vomiting, anemia, abdominal pain, dysgeusia (distortion of the sense of taste), constipation, decreased appetite, diarrhea, thrombocytopenia (deficiency of platelets in the blood), and dyspnea (difficult breathing) 
.On October 12, 2012, the European EMA granted orphan designation to Clovis Oncology UK Limited, United Kingdom, for rucaparib for the treatment of ovarian cancer .
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.